MLYS
Price:
$12.06
Market Cap:
$600.21M
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.[Read more]
Industry
Biotechnology
IPO Date
2023-02-10
Stock Exchange
NASDAQ
Ticker
MLYS
According to Mineralys Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 502.94M. This represents a change of 10.00% compared to the average of 457.23M of the last 4 quarters.
The mean historical Enterprise Value of Mineralys Therapeutics, Inc. over the last ten years is 590.12M. The current 502.94M Enterprise Value has changed 8.42% with respect to the historical average. Over the past ten years (40 quarters), MLYS's Enterprise Value was at its highest in in the December 2021 quarter at 709.59M. The Enterprise Value was at its lowest in in the September 2022 quarter at -48859462.36.
Average
590.12M
Median
687.64M
Minimum
261.91M
Maximum
723.30M
Discovering the peaks and valleys of Mineralys Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual Enterprise Value = 723.30M
Minimum Annual Increase = -60.66%
Minimum Annual Enterprise Value = 261.91M
Year | Enterprise Value | Change |
---|---|---|
2023 | 261.91M | -60.66% |
2022 | 665.70M | -6.19% |
2021 | 709.59M | -1.89% |
The current Enterprise Value of Mineralys Therapeutics, Inc. (MLYS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
545.73M
5-year avg
590.12M
10-year avg
590.12M
Mineralys Therapeutics, Inc.’s Enterprise Value is
Company | Enterprise Value | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mineralys Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Mineralys Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Mineralys Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Mineralys Therapeutics, Inc. (MLYS)?
What is the 3-year average Enterprise Value for Mineralys Therapeutics, Inc. (MLYS)?
What is the 5-year average Enterprise Value for Mineralys Therapeutics, Inc. (MLYS)?
How does the current Enterprise Value for Mineralys Therapeutics, Inc. (MLYS) compare to its historical average?